TISIDB

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.
Domain	PF02947 flt3 ligand
Function	Stimulates the proliferation of early hematopoietic cells by activating FLT3. Synergizes well with a number of other colony stimulating factors and interleukins.

> Gene Ontology [ TOP ]
Biological Process	GO:0000768 syncytium formation by plasma membrane fusion GO:0001773 myeloid dendritic cell activation GO:0001779 natural killer cell differentiation GO:0001894 tissue homeostasis GO:0002158 osteoclast proliferation GO:0002274 myeloid leukocyte activation GO:0002521 leukocyte differentiation GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0006949 syncytium formation GO:0007520 myoblast fusion GO:0010830 regulation of myotube differentiation GO:0010831 positive regulation of myotube differentiation GO:0014902 myotube differentiation GO:0030098 lymphocyte differentiation GO:0030101 natural killer cell activation GO:0030885 regulation of myeloid dendritic cell activation GO:0032814 regulation of natural killer cell activation GO:0032816 positive regulation of natural killer cell activation GO:0032823 regulation of natural killer cell differentiation GO:0032825 positive regulation of natural killer cell differentiation GO:0035162 embryonic hemopoiesis GO:0042692 muscle cell differentiation GO:0045445 myoblast differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045661 regulation of myoblast differentiation GO:0045663 positive regulation of myoblast differentiation GO:0045787 positive regulation of cell cycle GO:0048568 embryonic organ development GO:0048871 multicellular organismal homeostasis GO:0048872 homeostasis of number of cells GO:0048873 homeostasis of number of cells within a tissue GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0051146 striated muscle cell differentiation GO:0051147 regulation of muscle cell differentiation GO:0051149 positive regulation of muscle cell differentiation GO:0051153 regulation of striated muscle cell differentiation GO:0051155 positive regulation of striated muscle cell differentiation GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0060142 regulation of syncytium formation by plasma membrane fusion GO:0060143 positive regulation of syncytium formation by plasma membrane fusion GO:0060249 anatomical structure homeostasis GO:0070661 leukocyte proliferation GO:0070663 regulation of leukocyte proliferation GO:0070665 positive regulation of leukocyte proliferation GO:0071838 cell proliferation in bone marrow GO:0071839 apoptotic process in bone marrow GO:0071863 regulation of cell proliferation in bone marrow GO:0071864 positive regulation of cell proliferation in bone marrow GO:0071865 regulation of apoptotic process in bone marrow GO:0071866 negative regulation of apoptotic process in bone marrow GO:0090289 regulation of osteoclast proliferation GO:0090290 positive regulation of osteoclast proliferation GO:1901739 regulation of myoblast fusion GO:1901741 positive regulation of myoblast fusion GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis
Molecular Function	GO:0005125 cytokine activity GO:0030971 receptor tyrosine kinase binding GO:1990782 protein tyrosine kinase binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0031233 intrinsic component of external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04640 Hematopoietic cell lineage
Reactome	R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-449147: Signaling by Interleukins

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FLT3LG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between FLT3LG and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16651446	Sarcoma	Promote immunity (infiltration)	We have observed that the treatment of BALB/c mice bearing syngeneic CMS4 sarcomas with the combination of recombinant Flt3 ligand and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) for five sequential days is sufficient to optimize the number of tumor-infiltrating dendritic cells (TIDC).
21505426	Glioblastoma	Promote immunity	In a model of GBM recurrence, we demonstrate that Flt3L/TK mediated immunological memory is capable of recognizing brain tumor neoantigens absent from the original treated tumor. These data demonstrate that the Flt3L/TK gene therapeutic approach can induce systemic immunological memory capable of recognizing a brain tumor neoantigen in a model of recurrent GBM.

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FLT3LG in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FLT3LG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.119	0.764
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.219	0.879
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.38	0.669
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.592	0.139
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	1.232	0.353
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.219	0.891
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.472	0.33
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.357	0.0702
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.562	0.502
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.911	0.117
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.682	0.375
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.14	0.265

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FLT3LG in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FLT3LG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FLT3LG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FLT3LG. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FLT3LG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FLT3LG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FLT3LG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FLT3LG
Name	fms-related tyrosine kinase 3 ligand
Aliases	FL; FLT3L; flt3 ligand; SL cytokine
Chromosomal Location	19q13.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FLT3LG collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FLT3LG